Sometimes it seems much more is unknown about multiple myeloma than is known.
Though considered a rare disease, multiple myeloma is the second-most common type of blood cancer and is diagnosed in about 32,000 people a year in the U.S.
If you have been diagnosed with multiple myeloma — or are the caregiver for someone with multiple myeloma — plan to join us Saturday, Nov.
If you've received a diagnosis of MGUS or smoldering myeloma, you may wonder what the chances are that they will turn into multiple myeloma. Dr. Jens Hillengass explains.
The U.S. Food and Drug Administration approved a new indication for the oral drug lenalidomide (brand name Revlimid) as a maintenance therapy for multiple myeloma patients following autologous hematopoietic stem cell transplant (ASCT), also known as autologous blood and marrow transplant (BMT).
March is Myeloma Awareness Month. At Roswell Park we’re working year-round to uncover new ways of understanding this disease in order to develop new treatment methods and improve long-term survival rates for patients.
Roswell Park recently honored March as Myeloma Awareness Month and I want to share with you some of the exciting research being done regarding multiple myeloma treatment.